ClinicalTrials.gg
CompletedNCT04706741LINNAEAUpdated Feb 12, 2024

A Trial of the Efficacy and Safety of Izokibep in the Treatment of Non-anterior Uveitis

A Phase 2 interventional study of Izokibep and Prednisone/Prednisolone in Uveitis, sponsored by ACELYRIN Inc.. Completed at 4 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-02-12.

Sponsored by ACELYRIN Inc. · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was Aug 2022, 4 years 2 months ago, and no results have been posted to the registry; the sponsor requested a delay in submitting them in Aug 2023.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
7
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 139 studies in Uveitis with a site in United States — 7 open to participants now, 11 under way, 1 of them phase 3. Uveitis · United States.

Enrollment
73rd of 100
7 · median 19
Started
2022
with 8 others
Phase 2
28 of 139
none open now
Registered
122nd of 139
by date

Among the 139 studies in Uveitis with a site in United States, this one is the 73rd largest by enrollment of the 100 interventional ones that give a count, is one of 9 that started in 2022, is one of 28 in phase 2, and was the 122nd registered.

Uveitis

300 studies on the registry are indexed under Uveitis; 33 are open to participants now.

Browse Uveitis studies →

Open to participants now

7 of the 139 studies in Uveitis with a site in United States are open now. Recruiting first, the newest first:

2 more — sign in →

All 7 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 23 Uveitis studies recruiting now, 14 (61%) set no upper age limit and 9 (39%) stop at 75 or younger; 10 take children under 18; 5 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 139 studies in Uveitis with a site in United States, or all of them as a file.
02

Study summary

This is a multicenter, phase 2 trial to explore the efficacy and safety of Izokibep (ABY-035) in treating disease activity in patients with non-Infectious Intermediate, Posterior, Pan-Uveitis with significant disease activity at BL despite treatment with stable doses of corticosteroids (≥7 to ≤40 mg/day oral prednisolon or equivalent).

Read the detailed description

This is a multicenter, phase 2 trial to explore the efficacy and safety of Izokibep (ABY-035) in treating disease activity in patients with non-Infectious Intermediate, Posterior, Pan-Uveitis with significant disease activity at BL despite treatment with stable doses of corticosteroids (≥7 to ≤40 mg/day oral prednisolon or equivalent).

03

Conditions studied

  • Uveitis

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. ≥18 years of age at SCR
  2. Previously documented medical history with diagnosed unilateral or bilateral NIIPPU
  3. Active disease at BL defined by the presence of at least 1 of the following criteria in at least one eye despite treatment with stable doses of for at least 2 weeks:

    1. Active, inflammatory, chorioretinal and/or inflammatory retinal vascular lesion by Dilated Indirect Ophthalmoscopy (DIO), Fundus Photography, Fluorescein angiography (FA), spectral-domain optical coherence tomography (SD-OCT) to determine whether a lesion is active or inactive (the central reader's assessment using FA, FP, and or SD-OCT is required to confirm eligibility).
    2. ≥2+ vitreous haze ( NEI/SUN criteria) by DIO and Fundus Photography (the central reader's assessment using Fundus Photography is required to confirm eligibility).
  4. On treatment with oral corticosteroids (≥7 to ≤40 mg/day oral prednisolon or equivalent) at a stable dose for at least 2 weeks before BL

Exclusion criteria

Exclusion Criteria:

  1. Subject with isolated anterior uveitis
  2. Subject with Occlusive Behçet's disease, Acute Posterior Multifocal Placoid Pigment Epitheliopathy, Acute Posterior Pigment Epithelitis, Multiple Evanescent White Dot Syndrome, Punctate Inner Choroiditis or serpiginous choroidopathy
  3. Subject with confirmed or suspected infectious uveitis, including but not limited to infectious uveitis due to TB, syphilis, cytomegalovirus, Lyme disease, toxoplasmosis, Human T-Lymphotropic Virus Type 1 infection, Whipple's disease, herpes zoster virus, and herpes simplex virus
  4. Subject with corneal or lens opacity that precludes visualization of the fundus or that likely requires cataract surgery during the duration of the trial
  5. Planned (elective) eye surgery within 80 weeks after BL
  6. History of prior refractive laser surgery, retinal laser photocoagulation, or neodymium-doped yttrium aluminium garnet posterior capsulotomy within 30 days before BL
  7. History of any other prior ocular surgery within 90 days before BL
  8. Subject with intraocular pressure (IOP) of ≥25 mmHg while on ≥2 glaucoma medications or evidence of glaucomatous optic nerve injury
  9. Subject with severe vitreous haze that precludes visualization of the fundus at BL
  10. Subject has a for mydriatic eye drops OR subject cannot be dilatated sufficiently well to permit good fundus visualization
  11. Subject with BCVA \<20 letters (ETDRS) in at least one eye at BL
  12. Subject with intermediate uveitis or panuveitis who has presence or history of whitish exudates on the inferior pars plana (snowbanking) or vitreal inflammatory aggregates (snowballs) in combination with a medical history or signs or symptoms suggestive of a demyelinating disease such as multiple sclerosis
  13. Subject with proliferative or severe non-proliferative diabetic retinopathy or macular edema due to diabetic retinopathy
  14. Subject with neovascular/wet age-related macular degeneration
  15. Subject with an abnormality of the vitreo-retinal interface (i.e., vitreomacular traction, epiretinal membranes, etc.) with the potential for macular structural damage independent of the inflammatory process
  16. Subject with a history of active scleritis within 12 months of SCR Criteria that relate to comorbidity
  17. Uncontrolled inflammatory bowel disease
  18. Infection requiring treatment with IV anti-infectives within 30 days before BL or oral anti-infectives within 14 days before BL
  19. Subject with any active infection that based on the investigator's clinical assessment makes the subject an unsuitable candidate for the trial
  20. History or any signs of lymphoproliferative disease, or a known or a history of malignancy within the previous 3 years (except for basal cell or squamous cell carcinoma of the skin that had been fully excised with no evidence of recurrence) Criteria that relate to laboratory testing
  21. A positive test for subclinical/latent TB infection (i.e. positive QuantiFERON®-TB Gold test or equivalent product) suggestive of TB at SCR will require that the subject is thoroughly evaluated for active tuberculosis. If the subject is diagnosed with latent TB and active TB can be ruled out, the subject can be included if the subject has gone through an adequate course of prophylaxis as per local standard of care 12 weeks prior to SCR.
  22. Positive Fluorescent treponemal (FTA)- absorption test (syphilis)
  23. Subject with intolerance to high-dose oral (equivalent to oral prednisolon 1 mg/kg/day or 60 mg/day)
  24. The subject has received any biologic therapy (including ABY-035 or any other IL-17i or IL-17 receptor inhibitor, e.g. secukinumab, ixekizumab, brodalumab or anti-TNF-alpha therapy) within 8 weeks before BL.
  25. Subject on >1 concomitant non-biologic NCSIT
  26. Subject on 1 concomitant non-biologic NCSIT:

    a) But the medication is not listed as permissible b) The medication is listed as permissible, but the dose has not been stable within the last 3 months before BL c) The medication is listed as permissible, but the dose exceeds the allowable level; to be acceptable, the dose needs to be: i) Methotrexate (MTX) ≤25 mg/week ii) CsA ≤4 mg/kg/day iii) Mycophenolate mofetil ≤2 grams/day or an equivalent drug to mycophenolate mofetil (e.g., mycophenolic acid) at an equivalent dose approved by the Medical monitor iv) Azathioprine ≤175 mg/day v) Tacrolimus (oral formulation) ≤8 mg/day

28] The subject has received Retisert®, Iluvien®, or Yutiq® (glucocorticosteroids implant) within 3 years before BL or who has had complications related to the device. The subject has had any of these glucocorticosteroids implant (glucocorticosteroid implant) removed within 90 days before BL or has had complications related to the removal of the device 29] The subject has received intraocular or periocular corticosteroids within 90 days before BL 30] The subject has received Ozurdex® (dexamethasone implant) within 6 months before BL 31] The subject has received intravitreal methotrexate within 90 days before BL 32] The subject has received intravitreal anti- Vascular Endothelial Growth Factor (VEGF) therapy:

  1. within 45 days of BL for Lucentis® (ranibizumab) or Avastin® (bevacizumab)
  2. or within 60 days of BL for anti-VEGF Trap (aflibercept)
  3. or within 84 days of BL for Beovu® (brolucizumab) 33] Subject on systemic carbonic anhydrase inhibitor within 1 week before SCR 34] Subject on cyclophosphamide within 30 days before BL 35] Prior or current use of chlorambucil
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
7 participants (actual)

Study arms

  • Experimental
    Izokibep and maintenance corticosteroid dose

    Izokibep+ Prednisolon/Prednisone

    Drug: Izokibep · Drug: Prednisone/Prednisolone

Interventions

06

What researchers measure

Primary outcomes

  1. Complete Response

    Complete Response is defined as Yes/No by visit by meeting at least 1 of the following criteria in at least one eye: 1. Inflammatory, chorioretinal and/or inflammatory retinal vascular lesions - No such active lesions; all prior lesions appear inactive 2. ACC Count - Trace or absent (0.5+ or 0) 3. Vitreous Haze - Trace or absent (0.5+ or 0)

    Time frame: BL to Week 10

07

Study locations

4 sites
  • Research Site
    Los Angeles, California 90211, United States
  • Research Site
    Palo Alto, California 94303, United States
  • Research Site
    Hagerstown, Maryland 21740, United States
  • Research Site
    Plano, Texas 75075, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2022 to primary completion in Aug 2022, 7 months.

Of 17 phase 2 interventional studies under Uveitis, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 37. This study's 7 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 11, 2021
First posted
Jan 13, 2021
StartActual
Jan 6, 2022
Primary completionActual
Aug 25, 2022
CompletionActual
Nov 14, 2022
Results delay requested
Aug 7, 2023
Last update
Feb 12, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 12, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04706741
Lead sponsor
ACELYRIN Inc.
Responsible party
Sponsor
First posted
Jan 13, 2021
Start date
Jan 6, 2022
Primary completion
Aug 25, 2022
Completion
Nov 14, 2022
Last update
Feb 12, 2024

Study contacts

Donald Betah, MD
study director · ACELYRIN Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Izokibep

Start the discussion